Navigation Links
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/17/2008

Afdhal, N.H. et al. General Session 1, Thursday, April 24, 3:10 p.m., Hall A.

PEGINTRON Poster Presentations

Sustained virologic response after peginterferon alfa-2b and ribavirin treatment predicts long-term clearance of HCV at 5-year follow-up. Manns, M. et al.

Platelet count predicts sustained viral response (SVR) in the retreatment of previous interferon/ribavirin non-responders (NR): results from the EPIC3 program. Poynard, T. et. al.

Impact of viral load and cirrhosis on treatment outcome in HCV genotype 3-infected patients: results of the Canadian POWeR program. Marotta, P.J. et al.

The EASL Inaugural Poster Session and Welcome Reception will take place in the Poster Hall on Thursday, April 24, beginning at 7:00 p.m.

Boceprevir Oral Presentations

Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness. Schiff, E. et al. General Session 3, Saturday, April 26, 9:30 a.m., Hall A.

Interim results from HCV SPRINT-1: RVR/EVR from Phase II study of boceprevir plus PEGINTRON (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 CHC. Kwo, P. et al. Late-Breaker Parallel Session 16, Saturday, April 26, 5:45 p.m. Hall A.

Clonal analysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders treated with boceprevir (SCH503034). Susser, S. et al. Parallel Session 7, Friday April 25, 5:00 p.m., Hall 000.

Schering-Plough Media/Advocate Roundtable

Treating HCV Now and in the Future -- the Right Therapy for the Right Patient: What are the implications of the IDEAL study? Saturday, April 26, 6:30-8:00 p.m., Milan Convention Center, Room 4.

An expert panel of leading clinical investigators, key opinion leaders and advocates will lead a roundtable discussion following a review of the results of the IDEAL study and other recent clinical studies to address the implications for current therapy and
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

5

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
2. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
3. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
4. Schering-Plough Reports Top-Line Results of the IDEAL Study
5. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
6. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
7. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
8. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
11. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Accuray Incorporated (Nasdaq: ARAY ), ... announced today that the first CyberKnife® Robotic Radiosurgery ... University Hospital of Liege. ,, The University ... of the largest hospitals in Euregio, a cross-country ... a full range of cancer treatments, University Hospital ...
(Date:12/14/2009)... Inc. (Nasdaq: MYL ) today announced that ... Index Dec. 21. Mylan,s common shares will also ... Chairman and CEO Robert J. Coury said: "We ... followed index of leading companies. This development marks ... the rapid growth and strong potential of our ...
(Date:12/14/2009)... The U.S. Food and Drug Administration ... Injectable Suspension for the treatment of schizophrenia in ... LLY ) announced today. ZYPREXA RELPREVV, a long-acting ... up to four weeks. ,, Different from both ... antipsychotics allow for stable concentrations of the active ...
Breaking Medicine Technology:First CyberKnife in Belgium to be Installed at Leading University Hospital 2First CyberKnife in Belgium to be Installed at Leading University Hospital 3Mylan Added to NASDAQ-100 Index 2FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 2FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 3FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 4FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 5FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 6FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 7FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 8Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 14956 1Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 14956 2Zimmer Holdings to Present at 21st Annual Piper Jaffray Health Care Conference 6502 1Orexigen 28R 29 Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635 28c 29 284 29 6498 1Orexigen 28R 29 Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635 28c 29 284 29 6498 2Orexigen 28R 29 Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635 28c 29 284 29 6498 3
... Introduction ,Automation continues to gain importance ... increasing test consolidation, rising demands from clinicians ... shortage of licensed medical technologists. Ultimately, the ... better equipped to meet these modern demands. ...
... Editor ,Since the first system was ... clinical medicine and patient care. During the 1960s, ... blood gases were considered "the most important laboratory ... www.bloodgas.org article by Dr. John Severinghaus, inventor of ...
Other Medicine Technology:Optimizing Quality Control Data Management 2Optimizing Quality Control Data Management 3Optimizing Quality Control Data Management 4Optimizing Quality Control Data Management 5Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 2Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 3Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 4
(Date:12/14/2009)... hadn,t spread, study finds , , MONDAY, Dec. 14 (HealthDay ... death in male colon cancer survivors, researchers report. , ... men who,d been treated for stage I, stage II ... (nonmetastatic cancer). Every two years, the men were sent ... disease diagnoses, as well as their physical activity. A ...
(Date:12/14/2009)... are linked to an increased risk of certain cancers. ... synthetic insulin preparation marketed under the trade name Lantus), ... cancers than other insulins or oral glucose lowering medications. ... important factors such as obesity that may have driven ... large randomized trial designed to examine another aspect of ...
(Date:12/14/2009)... and Accurately for Biopsy , ... ... Diagnostics announced today that the U.S. Food and Drug Administration ... molecular imaging biopsy guidance. , , ,GammaLMc® is a ... Camera. The GammaLMc® (GL) system will help doctors accurately locate ...
(Date:12/14/2009)... show consistent rate of lacerations, accidental ingestion of ... Dec. 14 A new study from ... found that holiday decorations, particularly glass ornaments, are ... the season. A review of records from Children,s ... injuries per year, more than half of these ...
(Date:12/14/2009)... Only about one in 2,000 people in the United States ... the unfortunate few. , Ms. Wilcox,s tumor was a classic ... problems were mistaken for blocked sinuses. , "For several months, ... nose," recalled the resident of Goldthwaite, a town of less ... felt a fullness, but I didn,t take that as something ...
Breaking Medicine News(10 mins):Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 2Health News:Dilon Diagnostics Gamma-Guided Localization System Cleared by FDA 2Health News:Parents: Be Mindful of Hazardous Holiday Ornaments 2Health News:Parents: Be Mindful of Hazardous Holiday Ornaments 3Health News:Minimally invasive surgery removes sinus tumor without facial disfiguration 2
... Ramanathapuram District Collector, K. Sellamuthu, has ordered distribution of ... // such as tea stalls, hair cutting saloons ... are the places where large number of public gather. ... the Tamilnadu State AIDS Control Society (TANSACS), according to ...
... exception. To all those who wish kick the habit and ... Smokers // world over are swearing by Laser ... likened to a modern form of acupuncture has recorded higher ... most other smoking cessation programmes. For the first time, residents ...
... that is on the migratory route of wild birds had so ... ,But the latest news about the death of a 14-year-old ... only in Asia with the death toll about 70. ... being the cause of death of the Turkish boy. The boy ...
... of Padua have found that the some complications ... and immediately after birth) could play a major role ... as anorexia nervosa and bulimia nervosa. ,Previous ... by a complex interplay of genetic and environmental factors. ...
... of health reports that infectious diseases in China has ... and eradication// programs organized by the Chinese government but, ... urban population still there is a threat for infectious ... and malnutrition. China has seen a drop in air ...
... doctors of Indian origin live in a state of penury in ... of them even have decent // lodgings. This is the ... to serve in the country in 2001, which had resulted in ... ,Most of them are faced with discrimination and unemployment ...
Other Medicine News:Health News:Zap the butt (cigarette) with Laser Therapy 2Health News:Complications During Delivery Related To Eating Disorders 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: